|
|
Apixaban, a Novel Oral Anticoagulant, Use to Resolute Arterial Patency in Radial ArteryOcclusion Due to Cardiac Catheterization; A Pilot Randomized Clinical Trial
|
|
|
|
|
نویسنده
|
amirpour afshin ,zavar reihaneh ,seifipour amir ,sadeghi masoumeh ,shirvani ehsan ,kermani-alghoraishi mohammad ,sanei hamid ,hashemi jazi mohammad ,pourmoghaddas ali ,khosravi farsani alireza ,zarepour ehsan ,safaei ali ,hassannejad razieh
|
منبع
|
arya atherosclerosis - 2023 - دوره : 19 - شماره : 6 - صفحه:18 -26
|
چکیده
|
Introduction: in recent years, transradial cardiac catheterization has become the preferred method.however, it can result in a significant complication known as radial artery occlusion (rao). the medicalmanagement of rao remains controversial, especially with the emergence of novel oral anticoagulants.nevertheless, there is limited data on the use of these agents for treating rao, which is the focus of thisstudy using apixaban.method: this pilot double-blinded randomized clinical trial involved 30 patients who developed raofollowing transradial coronary angiography. the patients were randomly assigned to receive either apixaban(2.5 mg twice daily) or a conservative approach for 30 days. doppler ultrasonography was performed atbaseline and at the end of the intervention to assess radial artery diameter and the resolution of arterialpatency. demographic, medical, medication, and clinical characteristics were collected.results: the mean age of the studied population was 59.43±12.14 years, and the majority were males(60%). radial artery resolution was observed in 21 (70%) patients, independent of medication use. therewas no significant association between resolution and age (p-value=0.62), gender (p-value=0.74), body massindex (p-value=0.23), smoking (p-value=0.64), diabetes (p-value=0.999), hypertension (p-value=0.74),statins (p-value=0.999), antiplatelet therapy (p-value=0.999), length of angiography (p-value=0.216), orfollow-up arterial diameter (p-value=0.304). recanalization occurred in 13 (86.7%) cases in the apixabantreatment group, compared to 8 (53.3%) individuals in the control group, indicating a significant difference(p-value=0.046).conclusion: the study findings suggest no demographic, medical, medication, or clinical factors wereassociated with arterial recanalization. however, a one-month treatment with apixaban at a dose of 2.5 mgtwice daily appeared to be effective.
|
کلیدواژه
|
Apixaban ,Anticoagulants ,Coronary angiography ,Catheterization ,Ultrasonography
|
آدرس
|
isfahan university of medical sciences, cardiac rehabilitation research center, cardiovascular research institute, iran, isfahan university of medical sciences, isfahan cardiovascular research center, cardiovascular research institute, iran, isfahan university of medical sciences, interventional cardiology research center, cardiovascular research institute, Iran, isfahan university of medical sciences, cardiac rehabilitation research center, cardiovascular research institute, iran, isfahan university of medical sciences, interventional cardiology research center, cardiovascular research institute, iran, isfahan university of medical sciences, interventional cardiology research center, cardiovascular research institute, iran, isfahan university of medical sciences, interventional cardiology research center, cardiovascular research institute, iran, isfahan university of medical sciences, faculty of medicine, department of cardiology, Iran, isfahan university of medical sciences, faculty of medicine, department of cardiology, iran, isfahan university of medical sciences, faculty of medicine, department of cardiology, iran, isfahan university of medical sciences, isfahan cardiovascular research center, cardiovascular research institute, Iran, isfahan university of medical sciences, isfahan cardiovascular research center, cardiovascular research institute, iran, isfahan university of medical sciences,, isfahan cardiovascular research center, cardiovascular research institute, Iran
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|